ERBB2 and neoplasm: In the MembraneQuant’s calculation, scoring is purely assessed by cellularity and percentage, and the ASCO/CAP recommendation of scoring tumor cells within a contiguous area appreciable at low power [9] is not incorporated and can contribute to overscoring of HER2 IHC.